Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE DATED JULY 1, 2011 - TENAX THERAPEUTICS, INC. | rrd316908_35265.htm |
EX-10.1 - FORM OF CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT - TENAX THERAPEUTICS, INC. | rrd316908_35263.htm |
Delaware
|
26-2593535
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation)
|
Identification No.)
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The Offering was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 thereunder. The aggregate gross proceeds to the Company from the Offering were approximately $4.9 million, excluding any proceeds from the exercise of any Warrants, and the aggregate placement agent fees were approximately $297,000.
Summaries of the terms of the Notes, Warrants and Original Purchase Agreement were included in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 22, 2011, and are incorporated herein by reference. Such summaries, and the foregoing summary of the Additional Purchase Agreement, do not purport to be complete and are subject to, and qualified in their entirety by, the forms of such documents attached hereto, which are incorporated herein by reference.
EXHIBIT No. DESCRIPTION
4.1 Form of Convertible Note (included in Exhibit 10.1)
Oxygen Biotherapeutics, Inc.
|
||||||||
Date: July 01, 2011
|
By:
|
/s/ Chris Stern
|
||||||
Chris Stern
|
||||||||
Chief Executive Officer
|
||||||||
Exhibit No.
|
Description
|
|
EX-10.1
|
Form of Convertible Note and Warrant Purchase Agreement
|
|
EX-99.1
|
Press Release Dated July 1, 2011
|